long-term rcc data with nivolumab
Published 7 years ago • 254 plays • Length 4:05Download video MP4
Download video MP3
Similar videos
-
1:53
dr. mcdermott on long-term benefit with nivolumab in rcc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
1:27
dr. hammers on nivolumab/ipilimumab data in rcc
-
1:08
dr. motzer on nivolumab/ipilimumab activity in rcc
-
1:16
dr. mcgregor on combination therapies with nivolumab, cabozantinib, and sunitinib in rcc
-
3:11
treatment options for intermediate/poor-risk rcc
-
1:52
dr. powles on monitoring immunotherapy effects in patients with rcc
-
1:21
dr. hammers on the long-term benefits of the checkmate-214 study in rcc
-
0:43
dr. pal on sequencing nivolumab in rcc
-
1:29
dr. bates on stimulating the immune system with nanoparticles in rcc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
0:59
dr. zibelman on determining treatments for patients with rcc
-
4:46
sbrt in combination with ipilimumab/nivolumab in mrcc
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc
-
1:58
dr. plimack on significance of checkmate-025 trial in rcc
-
1:54
dr. lenz on updated data from checkmate 142 with nivolumab ipilimumab in mcrc
-
1:10
dr. motzer on first-line treatment of metastatic rcc
-
2:25
dr. tykodi on the keynote-427 trial with pembrolizumab in rcc